Table 3 Vaccine status and incidence of COVID-19 post-vaccination
From: Multisystem Inflammatory Syndrome (MIS) following SARS-CoV-2 vaccinations; a systematic review
Variable | Total (n = 37) |
|---|---|
Number of doses before having MIS | |
 One dose | 20 (54.1) |
 Two doses | 16 (43.2) |
 Not reported | 1 (2.7) |
Name of vaccine | |
 Pfizer-BioNTech | 24 (64.9) |
 AstraZeneca | 2 (2.7) |
 Moderna | 5 (13.5) |
 Johnson and Johnson | 2 (5.4) |
 Inactivated SARS-CoV-2 vaccine | 1 (2.7) |
 Name not recorded | 3 (8.1) |
COVID-19 infection post-vaccine | |
 Yes | 4 (10.8) |
 No | 25 (67.6) |
 Not reported | 8 (21.6) |
COVID-19 exposure post-vaccine | |
 Yes | 2 (5.4) |
 No | 8 (21.6) |
 Not reported | 27 (73.0) |